Nucl Med Mol Imaging.  2021 Aug;55(4):162-172. 10.1007/s13139-021-00709-3.

Transarterial Radioembolization Agents: a Review of the Radionuclide Agents and the Carriers

• Alrfooh A
• Patel A
• Laroia S

• KMID: 2519269
• DOI: http://doi.org/10.1007/s13139-021-00709-3

Abstract

Liver tumors, both primary and secondary to metastatic disease, remain a major challenge, with an increasing incidence. In this context, taking advantage of the dual blood supply of the liver, and the fact that liver tumors derive majority of their blood supply from the hepatic artery, intraarterial therapies are gaining popularity. Intraarterial liver-directed therapy (IALDT) is the option when the surgery is not feasible due to the number of metastases or for other reasons. Transarterial radioembolization (TARE) is a specific type of IALDT, where a carrier particle/microsphere is labeled with a radioactive substance and then is injected into hepatic artery for therapeutic purposes. As this field is rapidly evolving, with multiple agents being investigated and being introduced into clinical practice, it is hard for the practitioners and researchers to encompass all the available information concisely. This article aims to present a comprehensive review of the prominent TARE technologies.

Keyword

Transarterial radioembolization ; Microspheres; Radionucleotides; Carrier molecules; Hepatocellular carcinoma